The data demonstrated significant differential expression of DHCR7 across various factors, including cancer stages, histological subtypes, molecular subtypes, nodal metastasis status, and TP53 mutation status in BLCA (Figure 11C–H). The gene discussed is DHCR7; the disease is bladder transitional cell carcinoma.